PDIA3 and cancer: In conclusion, PDIA1 and PDIA3 represent the most abundant isoforms in multiple cancer cell lines and are also bound to membranes and released extracellularly providing the rationale of the development of anti-PDIA1 and anti-PDIA3 therapy targeted to extracellular PDIs.